JPS6045516A - １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 - Google Patents
１α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤Info
- Publication number
- JPS6045516A JPS6045516A JP14132383A JP14132383A JPS6045516A JP S6045516 A JPS6045516 A JP S6045516A JP 14132383 A JP14132383 A JP 14132383A JP 14132383 A JP14132383 A JP 14132383A JP S6045516 A JPS6045516 A JP S6045516A
- Authority
- JP
- Japan
- Prior art keywords
- 1alpha
- hydroxyvitamin
- agent
- physiologically active
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title abstract description 10
- 239000013543 active substance Substances 0.000 title abstract description 4
- 239000012867 bioactive agent Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 4
- -1 1alpha-(OH)-D3 Chemical compound 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 239000003907 antipyretic analgesic agent Substances 0.000 abstract description 3
- 229960004676 antithrombotic agent Drugs 0.000 abstract description 2
- 239000007891 compressed tablet Substances 0.000 abstract description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 235000011293 Brassica napus Nutrition 0.000 description 2
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132383A JPS6045516A (ja) | 1983-08-02 | 1983-08-02 | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 |
| JP24470790A JPH03169818A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 |
| JP24470590A JPH03169817A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する血圧低下剤 |
| JP24470690A JPH03169820A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する血中脂質調節剤 |
| JP24470890A JPH03169819A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132383A JPS6045516A (ja) | 1983-08-02 | 1983-08-02 | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24470590A Division JPH03169817A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する血圧低下剤 |
| JP24470890A Division JPH03169819A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 |
| JP24470790A Division JPH03169818A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 |
| JP24470690A Division JPH03169820A (ja) | 1983-08-02 | 1990-09-14 | １α―ヒドロキシビタミンＤ↓３類を含有する血中脂質調節剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045516A true JPS6045516A (ja) | 1985-03-12 |
| JPH0319207B2 JPH0319207B2 (en]) | 1991-03-14 |
Family
ID=15289247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14132383A Granted JPS6045516A (ja) | 1983-08-02 | 1983-08-02 | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045516A (en]) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929610A (en) * | 1985-07-01 | 1990-05-29 | Hoffmann-La Roche Inc. | Composition which contain hydroxylated derivatives of vitamin D3 |
| JPH03169818A (ja) * | 1983-08-02 | 1991-07-23 | Kureha Chem Ind Co Ltd | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 |
| JPH03169819A (ja) * | 1983-08-02 | 1991-07-23 | Kureha Chem Ind Co Ltd | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 |
| WO2001030751A3 (en) * | 1999-10-25 | 2002-06-13 | Strakan Ltd | USES OF 1,25-DIHYDROXY-5,6-trans VITAMIN D COMPOUNDS AND DERIVATIVES THEREOF |
| WO2005011651A3 (en) * | 2003-07-30 | 2005-08-11 | Abbott Lab | Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| WO2006060765A3 (en) * | 2004-12-02 | 2007-01-04 | Abbott Lab | Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals |
| US7286295B1 (en) | 2005-11-30 | 2007-10-23 | Sandia Corporation | Microoptical compound lens |
| CN103202821A (zh) * | 2013-04-09 | 2013-07-17 | 青岛正大海尔制药有限公司 | 一种骨化三醇软胶囊及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5626819A (en) * | 1979-08-10 | 1981-03-16 | Chugai Pharmaceut Co Ltd | Preventive for hypoimmunity |
| JPS5852268A (ja) * | 1981-08-28 | 1983-03-28 | エフ・ホフマン―ラ ロシユ アーゲー | コレカルシフエロ−ル誘導体 |
| JPS58118516A (ja) * | 1981-12-29 | 1983-07-14 | Teijin Ltd | １α，２５−ジヒドロキシビタミンＤ↓３−２６，２３−ラクトンを含有するカルシユウム調節剤 |
| JPS58126862A (ja) * | 1981-11-02 | 1983-07-28 | リサ−チ・インステイチユ−ト・フオア・メデイスン・アンド・ケミストリ−・インコ−ポレ−テツド | １−ヒドロキシル化ビタミンｄ化合物の製法 |
-
1983
- 1983-08-02 JP JP14132383A patent/JPS6045516A/ja active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5626819A (en) * | 1979-08-10 | 1981-03-16 | Chugai Pharmaceut Co Ltd | Preventive for hypoimmunity |
| JPS5852268A (ja) * | 1981-08-28 | 1983-03-28 | エフ・ホフマン―ラ ロシユ アーゲー | コレカルシフエロ−ル誘導体 |
| JPS58126862A (ja) * | 1981-11-02 | 1983-07-28 | リサ−チ・インステイチユ−ト・フオア・メデイスン・アンド・ケミストリ−・インコ−ポレ−テツド | １−ヒドロキシル化ビタミンｄ化合物の製法 |
| JPS58118516A (ja) * | 1981-12-29 | 1983-07-14 | Teijin Ltd | １α，２５−ジヒドロキシビタミンＤ↓３−２６，２３−ラクトンを含有するカルシユウム調節剤 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03169818A (ja) * | 1983-08-02 | 1991-07-23 | Kureha Chem Ind Co Ltd | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 |
| JPH03169819A (ja) * | 1983-08-02 | 1991-07-23 | Kureha Chem Ind Co Ltd | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 |
| US4929610A (en) * | 1985-07-01 | 1990-05-29 | Hoffmann-La Roche Inc. | Composition which contain hydroxylated derivatives of vitamin D3 |
| WO2001030751A3 (en) * | 1999-10-25 | 2002-06-13 | Strakan Ltd | USES OF 1,25-DIHYDROXY-5,6-trans VITAMIN D COMPOUNDS AND DERIVATIVES THEREOF |
| WO2005011651A3 (en) * | 2003-07-30 | 2005-08-11 | Abbott Lab | Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| WO2006060765A3 (en) * | 2004-12-02 | 2007-01-04 | Abbott Lab | Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals |
| JP2008521935A (ja) * | 2004-12-02 | 2008-06-26 | アボット・ラボラトリーズ | 哺乳動物において、内膜過形成、平滑筋細胞増殖及び再狭窄を軽減するための、ビタミンｄ受容体を活性化する化合物の使用 |
| US7286295B1 (en) | 2005-11-30 | 2007-10-23 | Sandia Corporation | Microoptical compound lens |
| CN103202821A (zh) * | 2013-04-09 | 2013-07-17 | 青岛正大海尔制药有限公司 | 一种骨化三醇软胶囊及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0319207B2 (en]) | 1991-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4666701A (en) | Pharmaceutical and dietary compositions | |
| JP2722227B2 (ja) | 脂肪酸組成物 | |
| CZ20012947A3 (cs) | Pouľití esenciálních mastných kyselin pro prevenci kardiovaskulárních příhod | |
| JPH06166617A (ja) | 食品組成物 | |
| CA2043137A1 (en) | Essential fatty acid treatment | |
| EP0085579A2 (en) | Topical pharmaceutical compositions | |
| EP0139480B1 (en) | Topical preparations containing tars and fatty acids | |
| EP0734723A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| JPH05316998A (ja) | 食品組成物 | |
| US4910224A (en) | Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein | |
| JPS6045516A (ja) | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 | |
| US4898885A (en) | Pharmaceutica and dietary compositions | |
| JPH09509139A (ja) | 酪酸エステル細胞分化薬 | |
| AU625705B2 (en) | Pharmaceutical and dietary uses of fatty acids | |
| MXPA05008596A (es) | Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol. | |
| JPH0222732B2 (en]) | ||
| JP2543627B2 (ja) | 活性型ビタミンｄ含有治療剤 | |
| JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| JPS6011418A (ja) | 抗炎症剤 | |
| JPS60215624A (ja) | 消炎鎮痛剤 | |
| JPH03169818A (ja) | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 | |
| JPS6045533A (ja) | プロスタグランジン調節剤 | |
| Flower et al. | Mechanism of steroid induced inhibition of arachidonate oxidation | |
| JP2007532605A5 (en]) | ||
| JP2020090448A (ja) | アレルギー性結膜炎予防又は治療剤 |